Skip to main content

Dissecting the role of type I IFN as regulator of innate antifungal immunity

NIAID - National Institute of Allergy and Infectious Diseases

open
OpenLast verified: 2026-07-26

About This Grant

PROJECT SUMMARY Fungal pathogens present a significant risk to immunocompromised individuals because they contribute to increased morbidity and mortality worldwide. Aspergillus fumigatus (Af) is the main cause of invasive pulmonary aspergillosis (IA) and has been identified by the World Health Organization as a critical fungal pathogen for further study. These findings highlight the increasing incidence of IA and the medical need for new strategies to treat invasive fungal infections, such as Af. Myeloid cells, CCR2+ inflammatory monocytes (CCR2+Mo), and neutrophils are necessary for controlling pulmonary Af infection. CCR2⁺Mo gives rise to monocyte-derived dendritic cells (mo-DCs) and alveolar macrophages (AMs), which are key effector populations within the CD11c⁺ cell compartment. In previous studies, we found that CCR2+Mo depleted mice affect neutrophil responses due to a decreased ability of neutrophils to produce reactive oxygen species (ROS) and eliminate Af conidia. Furthermore, neutrophils play a critical role in regulating the antifungal response of CCR2+Mo and promote the differentiation of protective mo-DCs. In previous work to understand the mechanism of monocyte-dependent neutrophil regulation, the lab performed a systems biology approach based on differential neutrophil transcriptomics, which allowed us to identify a strong interferon signaling (IFNs) gene signature. Since STAT1 is key to IFNs, we performed survival studies and found that deleting STAT1 in CCR2+Mo succumbed to Af, impaired maturation of mo-DCs, and reduced ROS formation. Additionally, when we deleted STAT1 in CD11c+ cells, we found that it affected mortality and increased the fungal burden. This confirms that STAT1 expression on CCR2+Mo and CD11c+ cells is required for defense against Af. To assess the importance of Type I IFN, we infected mice with defective expression of the type I IFN receptor (IFNAR1), which developed IA due to their inability to control fungal growth. In a kinetic analysis of IFN-α expression following Af infection, we demonstrated a rapid induction of type I IFN with peak protein expression observed at 12 hours post-infection. Although we have previously shown that type I IFNs are essential for controlling Af, their specific contribution to antifungal immunity in CCR2⁺Mo and CD11c+ cells remains unclear. We hypothesize that type I IFNs are essential for regulating antifungal immunity through CCR2⁺Mo and CD11c+ cells by activating the IFNAR1, triggering STAT1-dependent signaling pathways that enhance defense mechanisms against infections caused by Af. Two specific aims are proposed: 1) to examine the role of type I IFNs in regulating the antifungal response of CCR2⁺Mo and 2) to elucidate the mechanisms of whether type I IFNs regulate the antifungal response of CD11c+ cells. Achieving the proposed objectives will uncover novel insights into how type I IFNs influence antifungal immune responses via CCR2⁺Mo and CD11c+ cells. These findings have the potential to reveal new immunological pathways that strengthen host defenses against Af and inform strategies to improve outcomes in individuals vulnerable to aspergillosis.

Grant Summary

Dissecting the role of type I IFN as regulator of innate antifungal immunity is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $47K for university, nonprofit, healthcare org. Applications are due 2029-05-31 (open). Check eligibility and apply with FindGrants.

Not quite the right fit?

Search 9,000+ open grants, or get matches ranked for your organization — free.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $47K

Deadline

2029-05-31

Complexity
Medium
  1. 1Confirm your organization is eligible for Dissecting the role of type I IFN as regulator of innate antifungal immunity from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Dissecting the role of type I IFN as regulator of innate antifungal immunity: Frequently Asked Questions

Who is eligible for the Dissecting the role of type I IFN as regulator of innate antifungal immunity?

Dissecting the role of type I IFN as regulator of innate antifungal immunity is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Dissecting the role of type I IFN as regulator of innate antifungal immunity provide?

Dissecting the role of type I IFN as regulator of innate antifungal immunity provides up to $47K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Dissecting the role of type I IFN as regulator of innate antifungal immunity deadline?

Applications for Dissecting the role of type I IFN as regulator of innate antifungal immunity are due 2029-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Dissecting the role of type I IFN as regulator of innate antifungal immunity?

To apply for Dissecting the role of type I IFN as regulator of innate antifungal immunity, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.